Analyze Diet
Veterinary journal (London, England : 1997)2009; 186(1); 106-109; doi: 10.1016/j.tvjl.2009.06.026

Evidence for a novel vasospastic transmitter system, neuromedin U, in the equine digital circulation.

Abstract: The brain-gut peptide neuromedin U (NMU) is a ligand for the G-protein-coupled receptors, NMU1 and NMU2. In humans, an extended form of this peptide, NMU-25, and the structurally related peptide, neuromedin S (NMS), both produce potent vasoconstriction in isolated blood vessels. The aim of this study was to determine whether NMU fulfilled criteria for controlling vasoreactivity in the equine digital circulation. NMU receptors were characterised in the equine digital artery and vein based on the pharmacological criteria of specific, saturable and high affinity binding. Immunoreactive peptide was detected in the equine digital artery and vein using anti-NMS antisera. [(125)I]-NMU-25 binding sites were localised to the smooth muscle layer and NMU-25 potently constricted the digital vein. This provides evidence for NMU as a transmitter in the equine digital circulation.
Publication Date: 2009-08-14 PubMed ID: 19683464DOI: 10.1016/j.tvjl.2009.06.026Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The study provides evidence for the role of a brain-gut peptide neuromedin U (NMU) as a regulator of blood vessel constriction in horse’s foot circulation.

Research Goals

  • The main aim of this research was to understand whether Neuromedin U (NMU), a brain-gut peptide, plays a role in controlling the vasoreactivity, i.e., the capacity of a blood vessel to constrict or dilate, in the circulation system of a horse’s foot, traditionally known as equine digital circulation.

Methodology

  • The investigators identified the NMU receptors in the blood vessels (artery and vein) of horse’s foot based on certain characteristics including specific, saturable, and high-affinity binding.
  • They also used anti-neuromedin S (NMS) antisera to determine the presence of neuromedin U. NMS is a peptide that’s structurally related to NMU and is also known for causing vasoconstriction in isolated blood vessels.
  • The identification of the [(125)I]-NMU-25 binding sites was made in the smooth muscle layer.

Findings

  • It was observed that NMU-25 could cause potent constriction of the digital vein in the foot of a horse. These findings led the researchers to believe that Neuromedin U serves as a vasospastic transmitter in equine digital circulation.

Conclusion

  • This research adds to the understanding of the regulation of blood flow in the equine digital circulation.
  • The results provided evidence for NMU serving as a vasoconstrictor, specifically in the smooth muscle layer of the digital vein in the vascular system of a horse’s foot.

Cite This Article

APA
Mitchell JD, Kuc RE, Maguire JJ, Davenport AP. (2009). Evidence for a novel vasospastic transmitter system, neuromedin U, in the equine digital circulation. Vet J, 186(1), 106-109. https://doi.org/10.1016/j.tvjl.2009.06.026

Publication

ISSN: 1532-2971
NlmUniqueID: 9706281
Country: England
Language: English
Volume: 186
Issue: 1
Pages: 106-109

Researcher Affiliations

Mitchell, John D
  • Clinical Pharmacology Unit, University of Cambridge, Level 6 Centre for Clinical Investigation, Box 110 Addenbrooke's Hospital, Cambridge CB2 2QQ, UK. apd10@medschl.cam.ac.uk
Kuc, Rhoda E
    Maguire, Janet J
      Davenport, Anthony P

        MeSH Terms

        • Animals
        • Hoof and Claw / blood supply
        • Horses
        • Neuropeptides / pharmacology
        • Receptors, Neurotransmitter / metabolism
        • Regional Blood Flow / drug effects
        • Vasoconstriction / drug effects

        Grant Funding

        • British Heart Foundation

        Citations

        This article has been cited 0 times.